Thursday, May 8, 2025

Latest

Antibe Therapeutics Pauses Otenaproxesul Trial After Exceeding Safety Threshold

Antibe Therapeutics Inc. (TSX: ATE) shared today that it is putting on pause the absorption, metabolism, and excretion study of its osteoarthritis pain treatment lead candidate otenaproxesul. This follows after the clinical study exceeded the pre-specified safety threshold.

The study is part of the drug candidate’s Phase III trial involving 42 subjects. Three of the subjects who were administered 100mg of otenaproxesul exhibited liver transaminase elevations exceeding five times the upper limit. The company, however, noted that other indicators of liver function for these subjects were normal.

These elevations were discovered during the 14-day in-clinic post-administration observation period for subjects who have completed the full drug administration period. Antibe relayed that these observations were unexpected based on the efficacy, safety, and pharmacokinetic studies previously conducted on the drug.

The firm said it plans to discuss the status of the paused study and its outlook with Health Canada.

Antibe Therapeutics last traded at $3.39 on the TSX.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Related News

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Antibe: Canaccord Lowers Price Target After Co-Leading $40.4 Million Financing

Wednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought...

Friday, February 26, 2021, 11:55:00 AM

Antibe Therapeutics To Raise $35.1 Million In Bought Deal

Money continues to be raised at a feverish pace in the capital markets, with Antibe...

Thursday, February 18, 2021, 07:30:48 AM

Antibe Therapeutics Proposes Share Consolidation To Enable Potential Nasdaq Listing

It appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it...

Wednesday, July 15, 2020, 10:04:38 PM